Ir al contenido

Diferencia entre revisiones de «Vigabatrina»

De Wikipedia, la enciclopedia libre
Explorar historial interactivamente
Contenido eliminado Contenido añadido
VisualWikitexto
listaref
 
m cm
 
(No se muestran 14 ediciones intermedias de 10 usuarios)
Línea 1: Línea 1:
[[Archivo:Vigabatrin Enantiomers Structural Formulae.png|thumb|Vigabatrina]]
{{drugbox
⚫
'''Vigabatrina''' (ácido ''RS'')-4-aminohex-5-enoico) es un [[Anticonvulsivante|agente antiepiléptico]] que inhibe el [[catabolismo]] del [[ácido gamma-aminobutírico|GABA]] por inhibición de la [[transaminasa GABA]]. Es una [[análogo]] de GABA, pero no es un agonista del [[receptor]].<ref name=what_is_vigabatrin>Long, Phillip W. [http://www.mentalhealth.com/drug/p30-s07.html "Vigabatrin."] Internet Mental Health. 1995–2003.</ref><ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885026/pdf/bcp0061-0246.pdf</ref> Se comercializa como '''Sabril''' por [[Sanofi-Aventis]].
| drug_name=Vigabatrin
Produce ceguera de efecto acumulativo.<ref>http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0365-66912007001100010</ref>
| verifiedrevid = 402874222
| IUPAC_name = (''RS'')-4-aminohex-5-enoic acid
| image = Vigabatrin.svg
| imagename = 1 : 1 mixture (racemate)
| width = 200
| CASNo_Ref = {{cascite|correct|CAS}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5463
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = GR120KRT6K
| InChI = 1/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
| InChIKey = PJDFLNIOAUIZSL-UHFFFAOYAL
| smiles = O=C(O)CCC(\C=C)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PJDFLNIOAUIZSL-UHFFFAOYSA-N
| CAS_number = 60643-86-9
| ATC_prefix = N03
| ATC_suffix = AG04
| ATC_supplemental =
| PubChem = 5665
| DrugBank = APRD00282
| C = 6 | H = 11 | N = 1 | O = 2
| molecular_weight = 129.157 g/mol
| bioavailability = 80–90%
| protein_bound = Nil
| metabolism = Almost no metabolic transformation occurs
| elimination_half-life = 5–8 hours in young adults, 12–13 hours in the elderly.
| pregnancy_AU = D
| legal_status = Not a controlled substance
| routes_of_administration = Oral
| excretion = [[Renal]]
}}


== Referencias ==
⚫
'''Vigabatrina''' es un [[Anticonvulsivante|agente antiepileptico]] que inhibe el [[catabolismo]] del [[ácido gamma-aminobutírico|GABA]] por inhibición de la [[transaminasa GABA]]. Es una [[análogo]] de GABA, pero no es un agonista del [[receptor]].<ref name=what_is_vigabatrin>Long, Phillip W. [http://www.mentalhealth.com/drug/p30-s07.html "Vigabatrin."] Internet Mental Health. 1995–2003.</ref> It is sold under the brand name '''Sabril'''.
{{listaref|2}}
{{listaref}}
==Indications==
===Epilepsy===
In Canada, vigabatrin is approved for use as an adjunctive treatment (with other drugs) in treatment resistant [[epilepsy]], [[complex partial seizure]]s, [[seizures|secondary generalized seizures]], and for monotherapy use in [[infantile spasm]]s in [[West syndrome]].<ref name=what_is_vigabatrin/>


{{control de autoridades}}
As of 2003, vigabatrin is approved in Mexico for the treatment of epilepsy that is not satisfactorily controlled by conventional therapy (adjunctive or monotherapy) or in recently diagnosed patients who have not tried other agents (monotherapy).<ref name=mexicanuses>[http://www.facmed.unam.mx/bmnd/plm/mex/productos/10130.htm DEF MEXICO: SABRIL] ''Diccionario de Especialdades Farmaceuticas.'' Edicion 49, 2003.</ref>
[[Categoría:Antiepilépticos]]

Vigabatrin is also indicated for monotherapy use in secondarily generalized [[tonic-clonic seizure]]s, [[seizures|partial seizure]]s, and in infantile spasms due to West syndrome.<ref name=mexicanuses/>

Revisión actual - 19:36 17 sep 2023

Vigabatrina

Vigabatrina (ácido RS)-4-aminohex-5-enoico) es un agente antiepiléptico que inhibe el catabolismo del GABA por inhibición de la transaminasa GABA. Es una análogo de GABA, pero no es un agonista del receptor.[1]​[2]​ Se comercializa como Sabril por Sanofi-Aventis. Produce ceguera de efecto acumulativo.[3]​

Referencias

[editar]
  1. ↑ Long, Phillip W. "Vigabatrin." Internet Mental Health. 1995–2003.
  2. ↑ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1885026/pdf/bcp0061-0246.pdf
  3. ↑ http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0365-66912007001100010
Obtenido de «https://es.wikipedia.org/eswiki/w/index.php?title=Vigabatrina&oldid=153815826»